Core Viewpoint - The company, Fengbei Biological Technology Co., Ltd., is set to go public on the Shanghai Stock Exchange, aiming to raise 1 billion yuan for expansion projects in the waste oil resource utilization sector [1][3]. Financial Performance - The company has experienced declining revenue and net profit from 2022 to 2024, with revenues of 1.71 billion yuan, 1.73 billion yuan, and 1.95 billion yuan, and net profits of 135.92 million yuan, 123.04 million yuan, and 115.32 million yuan respectively, indicating a downward trend [3]. - The sales prices of the company's main products have also shown a downward trend during the same period [3][4][5]. Product Pricing - The sales prices for the company's biodiesel formulation products decreased from 0.77 million yuan/ton in 2022 to 0.61 million yuan/ton in 2024, while industrial-grade mixed oil prices fell from 0.91 million yuan/ton to 0.62 million yuan/ton [4]. - The sales prices for biofuels and oil chemical products also declined, with biofuels dropping from 0.98 million yuan/ton to 0.73 million yuan/ton, and oil chemical products from 1.18 million yuan/ton to 0.89 million yuan/ton [5]. Inventory and Liabilities - The company's inventory has been increasing, with values of 104.24 million yuan, 198.38 million yuan, and 242.01 million yuan from 2022 to 2024, indicating a growing stockpile [6]. - The raw materials, primarily waste oil and industrial-grade mixed oil, accounted for a rising proportion of total inventory, increasing from 30.77% in 2022 to 40.71% in 2024 [6]. - The company has a significant amount of current liabilities, with total current liabilities of 373.14 million yuan, 336.64 million yuan, and 358.53 million yuan over the same period, primarily consisting of short-term loans and accounts payable [7][8]. Legal Issues - The company is involved in ongoing litigation related to a fire incident at a leased facility, which resulted in significant inventory losses and subsequent lawsuits from various parties [10][11].

Group 1 - The core viewpoint of the article is that Suzhou Fengbei Biotechnology Co., Ltd. has submitted its IPO registration to the Shanghai Stock Exchange, aiming to raise approximately 750 million yuan for various projects [1] - Fengbei Biotechnology is a high-tech enterprise in the field of comprehensive utilization of waste resources, primarily producing resource-based products from waste oils [1] - The company’s IPO was accepted on June 8, 2023, entered the inquiry stage on July 5, 2023, and was approved on August 7, 2025 [1] Group 2 - The funds raised from the IPO will be invested in projects including the construction of a 300,000-ton annual production facility for methyl oleate, a 10,000-ton industrial-grade mixed oil facility, a 50,000-ton agricultural microbial agent facility, a 10,000-ton compound microbial fertilizer facility, and the production of 50,000 tons of biodiesel and 8,200 tons of glycerin as by-products [1]

Core Viewpoint - Suzhou Fengbei Biotechnology Co., Ltd. has received approval for its initial public offering (IPO) on the Shanghai Stock Exchange, aiming to raise 1 billion yuan for various projects and working capital [1] Financial Performance - The company reported revenues of 1.709 billion yuan in 2022, 1.728 billion yuan in 2023, and projected 1.949 billion yuan in 2024, indicating a growth trend [1] - Net profits for the same years were 133 million yuan in 2022, 130 million yuan in 2023, and a forecast of 124 million yuan in 2024, showing a slight decline [1] - Basic earnings per share were 1.26 yuan in 2022, 1.21 yuan in 2023, and are expected to be 1.15 yuan in 2024, reflecting a downward trend [1] Key Financial Indicators - Revenue for 2024 is projected at 1.948 billion yuan, up from 1.728 billion yuan in 2023 and 1.709 billion yuan in 2022 [1] - The net profit attributable to shareholders is expected to be 123.82 million yuan in 2024, down from 129.71 million yuan in 2023 and 133.35 million yuan in 2022 [1] - The weighted average return on equity is forecasted to be 17.91% in 2024, a decrease from 22.43% in 2023 and 30.57% in 2022 [1]

Group 1 - The core viewpoint of the article is that Suzhou Fengbei Biotechnology Co., Ltd. has successfully passed the IPO review on the Shanghai Stock Exchange, indicating a positive step towards its public listing [1] - Fengbei Biotechnology is a high-tech enterprise in the field of comprehensive utilization of waste resources, primarily producing resource-based products from waste oils [1] - The company aims to raise approximately 750 million yuan through its IPO, which will be invested in various projects including the production of 300,000 tons of oleic acid methyl ester and 10,000 tons of industrial-grade mixed oil [1] Group 2 - The listing committee has requested Fengbei Biotechnology to explain the reasons and rationality behind the expected decrease or stability in sales and management expenses for 2024, despite anticipated adjustments in customer and product structures and continued revenue growth [1] - The committee also requires the company to address the authenticity of sales revenue and expenses related to industrial-grade mixed oil, considering the main operational data and performance changes for 2024 [1] - Additionally, the committee has asked Fengbei Biotechnology to assess the risks of declining biofuel revenue, the sustainability of industrial-grade mixed oil revenue growth, and the stability of the company's operating performance in light of changes in product structure and competitive advantages [2]

Group 1 - The core business of Suzhou Fengbei Biotechnology Co., Ltd. is in the field of comprehensive utilization of waste resources, primarily producing resource-based products from waste oils, forming a recycling industry chain of "waste oils - biofuels (biodiesel) - bio-based materials" [1] - Fengbei Biotechnology is currently applying for an IPO, with significant sales reported to its fifth-largest customer, Zhejiang Yibaoxin Biotechnology Co., Ltd., amounting to 61.0678 million yuan for the year 2024 [1] - There is a discrepancy in reported figures between Fengbei Biotechnology and Yibaoxin, as Yibaoxin's annual report indicates its largest supplier's procurement amount is only 54.9759 million yuan, which is over 6 million yuan less than Fengbei's reported sales [1] Group 2 - The third-largest accounts receivable customer for Fengbei Biotechnology at the end of 2024 is Nantong Borun New Energy Technology Co., Ltd., with an amount of 7.5839 million yuan, which did not appear in the previous year's top five accounts receivable customers [2] - Nantong Borun reported zero revenue and a net loss of 2.2739 million yuan for 2024, raising questions about the commercial rationale for its procurement from Fengbei Biotechnology [2] - The second-largest accounts receivable customer is Shandong Haike Chemical Co., Ltd., with an amount of 8.3443 million yuan, which has been issued a consumption restriction order by the Dongying Intermediate People's Court [2] Group 3 - The fundraising project for Fengbei Biotechnology's IPO aims to achieve an annual production capacity of 300,000 tons of oleic acid methyl ester, 10,000 tons of industrial mixed oil, 50,000 tons of agricultural microbial agents, 10,000 tons of compound microbial fertilizers, and by-products of 50,000 tons of biodiesel and 8,200 tons of glycerol [3] - The project is planned to be located in the Suzhou Zhangjiagang Free Trade Zone Yangtze River Chemical Park, with an industrial land area of 68,679.77 m², although there is a discrepancy with the local government’s public information indicating an additional land area of 68,745.9 m² (approximately 103.1 acres) [3]

Group 1 - The global carbon reduction policies and environmental awareness are creating new development opportunities for the waste oil resource utilization industry [1] - Suzhou Fengbei Biological Technology Co., Ltd. (Fengbei Bio) is a representative enterprise in the domestic waste oil resource utilization field, accelerating its expansion in domestic and international markets [1] - Fengbei Bio plans to issue no more than 35.9 million shares on the Shanghai Stock Exchange, with the public offering accounting for no less than 25% of the total share capital after issuance, aiming to raise 750 million yuan for various production projects [1] Group 2 - Fengbei Bio is a high-tech enterprise in the waste resource utilization sector, primarily focusing on the resource utilization of waste oil, with a secondary emphasis on oil chemical products [2] - The company is expanding the application boundaries of waste oil resource products into various industrial fields, particularly gaining a competitive advantage in the agricultural sector [2] - The capacity expansion will achieve three strategic values: breaking existing production constraints, leveraging economies of scale to reduce marginal costs, and consolidating market leadership to strengthen competitive advantages [2]

Group 1 - The core point of the article is the upcoming review meeting by the Shanghai Stock Exchange for the initial public offering (IPO) of Suzhou Fengbei Biotechnology Co., Ltd. on August 7, 2025 [1] - Fengbei Biotechnology, established in 2014, is a high-tech enterprise in the field of waste resource utilization, focusing on the comprehensive utilization of waste oil resources [1] - The company has developed a production chain from waste oil to biodiesel and bio-based materials, supported by significant R&D investments totaling 163 million yuan from 2022 to 2024 [1] Group 2 - The company has obtained 144 patents as of March 31, 2025, and has been recognized as a national "little giant" enterprise and a unicorn cultivation enterprise in Suzhou [1] - The funds raised from the IPO will be primarily invested in expanding production capacity for biodiesel, industrial mixed oils, glycerin, agricultural microbial agents, and composite microbial fertilizers [2] - The investment projects align with national circular economy strategies and are expected to enhance the company's production capacity and market position significantly [2]

Group 1 - Four companies are scheduled for IPO meetings, including Jieka Co., Ltd. for the Sci-Tech Innovation Board, Fengbei Bio for the Shanghai Main Board, and Kema Materials and Nante Technology for the Beijing Stock Exchange [1][2] - Fengbei Bio plans to raise the most funds, with an expected amount of 750 million yuan, aimed at projects such as a new annual production of 300,000 tons of oleic acid methyl ester and 10,000 tons of industrial-grade mixed oil [1][3] - Jieka Co., Ltd. and Nante Technology are expected to raise 676 million yuan and 286 million yuan, respectively [1] Group 2 - Fengbei Bio's main business focuses on the comprehensive utilization of waste oil resources, with a secondary focus on oil chemical products [3] - Jieka Co., Ltd. specializes in the research, development, production, and sales of collaborative robot complete products, as well as robot system integration [4] - Nante Technology is engaged in the research, development, production, and sales of precision mechanical components, while Kema Materials focuses on the development and production of dry and wet friction materials [5]

Core Viewpoint - The Shanghai Stock Exchange is set to review the IPO application of Suzhou Fengbei Biotechnology Co., Ltd. on August 7, 2025, marking a significant step for the company in the waste resource utilization sector [1] Company Summary - Suzhou Fengbei Biotechnology is a high-tech enterprise focused on the comprehensive utilization of waste resources, specifically converting waste oils into resource products [1] - The company’s IPO application was accepted on June 8, 2023, and it entered the inquiry phase on July 5, 2023 [1] - In the latest meeting materials, Fengbei Biotechnology has adjusted its fundraising projects, canceling the previously planned "supplementary working capital project," which was set to raise 250 million yuan [1] - Following the cancellation of the working capital project, the total amount intended to be raised in the IPO has been reduced to 750 million yuan, which will be allocated to several new projects, including the construction of a 300,000-ton/year oleic acid methyl ester plant, a 10,000-ton industrial mixed oil facility, a 50,000-ton agricultural microbial agent project, a 10,000-ton compound microbial fertilizer project, and the production of 50,000 tons of biodiesel and 8,200 tons of glycerol as by-products [1]

Group 1 - Four companies are set to present their IPO applications at the upcoming listing committee meetings [1] - Among the companies, Fengbei Biological is expected to raise the most funds, with a target of 750 million yuan for projects including the construction of a 300,000-ton oil acid methyl ester plant and various agricultural microbial products [2][4] - The other companies include Jieke Co., which aims to raise 676 million yuan, Nant Technology with a target of 286 million yuan, and Zhongcheng Consulting planning to raise 200 million yuan [2][6] Group 2 - Fengbei Biological focuses on the comprehensive utilization of waste oil resources and chemical products [4] - Jieke Co. specializes in the research, production, and sales of collaborative robot products, as well as automation system integration [5] - Zhongcheng Consulting provides professional technical services including engineering cost, bidding agency, and project management [6] - Nant Technology is engaged in the research, production, and sales of precision mechanical components [7]